Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:22PM ET
11.68
Dollar change
-0.18
Percentage change
-1.56
%
IndexRUT P/E- EPS (ttm)-0.52 Insider Own3.01% Shs Outstand293.59M Perf Week-0.13%
Market Cap3.45B Forward P/E29.44 EPS next Y0.40 Insider Trans-5.67% Shs Float286.50M Perf Month-9.84%
Income-151.58M PEG- EPS next Q-0.06 Inst Own106.62% Short Float11.31% Perf Quarter-19.09%
Sales399.36M P/S8.64 EPS this Y100.97% Inst Trans-4.34% Short Ratio10.34 Perf Half Y-9.35%
Book/sh0.55 P/B21.40 EPS next Y7948.83% ROA-20.18% Short Interest32.40M Perf Year4.15%
Cash/sh0.97 P/C12.05 EPS next 5Y- ROE-107.04% 52W Range9.70 - 14.57 Perf YTD-17.72%
Dividend Est.- P/FCF- EPS past 5Y22.84% ROI-25.39% 52W High-19.87% Beta0.75
Dividend TTM- Quick Ratio2.52 Sales past 5Y37.81% Gross Margin88.68% 52W Low20.36% ATR (14)0.46
Dividend Ex-Date- Current Ratio2.88 EPS Y/Y TTM37.05% Oper. Margin-18.40% RSI (14)41.46 Volatility3.68% 4.26%
Employees517 Debt/Eq2.78 Sales Y/Y TTM21.30% Profit Margin-37.96% Recom1.55 Target Price19.00
Option/ShortYes / Yes LT Debt/Eq2.73 EPS Q/Q41.97% Payout- Rel Volume0.45 Prev Close11.86
Sales Surprise0.64% EPS Surprise-90.31% Sales Q/Q30.63% EarningsFeb 28 BMO Avg Volume3.13M Price11.68
SMA20-3.64% SMA50-7.79% SMA200-5.62% Trades Volume664,414 Change-1.56%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Upgrade Morgan Stanley Equal-Weight → Overweight $15 → $20
Sep-09-22Initiated Morgan Stanley Equal-Weight $14
Apr-13-22Resumed Goldman Neutral $11
Jan-14-22Upgrade SVB Leerink Mkt Perform → Outperform $12 → $16
Nov-15-21Upgrade Stifel Hold → Buy $12 → $16
Sep-30-21Upgrade JP Morgan Neutral → Overweight $16
Jul-19-21Resumed BTIG Research Buy $15
May-27-21Initiated Needham Hold
May-21-21Initiated UBS Buy $16
Apr-14-21Upgrade Cantor Fitzgerald Neutral → Overweight $17
Mar-26-24 09:53AM
Mar-20-24 07:00AM
Mar-13-24 07:07AM
Mar-06-24 11:56PM
Mar-05-24 01:50PM
07:00AM Loading…
Mar-01-24 07:00AM
Feb-29-24 11:25AM
11:23AM
Feb-28-24 11:49PM
08:20AM
07:32AM
07:00AM
Feb-15-24 07:00AM
Feb-09-24 03:14PM
Feb-08-24 07:00AM
07:00AM Loading…
Feb-01-24 07:00AM
Jan-12-24 11:02PM
09:31AM
Jan-08-24 09:40AM
Jan-07-24 04:00PM
Jan-05-24 07:02PM
Jan-03-24 11:46AM
07:00AM
Dec-30-23 09:01AM
Dec-29-23 09:48AM
07:01AM
Dec-24-23 06:17AM
Dec-21-23 05:01AM
Dec-08-23 11:30AM
Dec-05-23 06:38AM
06:00AM Loading…
06:00AM
05:30AM
Nov-15-23 09:48AM
Nov-10-23 10:07AM
Nov-09-23 01:02PM
Nov-08-23 07:13AM
07:00AM
Nov-04-23 05:03AM
Nov-02-23 10:00AM
Nov-01-23 10:01AM
07:00AM
Oct-27-23 07:00AM
Oct-08-23 07:00AM
Oct-05-23 07:45PM
03:01AM
Oct-03-23 07:00AM
Oct-02-23 08:20AM
Oct-01-23 08:30PM
Sep-29-23 12:22PM
09:09AM
Sep-28-23 11:08AM
10:50AM
10:41AM
10:32AM
Sep-21-23 08:42AM
Sep-07-23 11:30AM
Sep-01-23 07:00AM
Aug-29-23 07:00AM
Aug-21-23 07:00AM
Aug-15-23 07:00AM
Aug-09-23 09:25AM
Aug-08-23 08:40AM
07:29AM
07:00AM
Aug-07-23 08:48AM
Aug-04-23 08:05AM
Jul-31-23 07:00AM
Jul-23-23 10:23AM
Jul-20-23 02:24PM
Jul-17-23 01:54PM
Jun-28-23 10:53AM
Jun-27-23 07:00AM
Jun-09-23 11:30AM
Jun-04-23 09:59AM
May-11-23 07:44AM
May-10-23 08:15AM
07:10AM
07:00AM
May-08-23 10:00AM
May-02-23 07:00AM
May-01-23 10:01AM
07:00AM
Apr-26-23 01:00PM
Apr-18-23 09:20AM
Apr-14-23 02:45PM
Mar-31-23 11:30AM
Mar-27-23 07:00AM
Mar-08-23 07:00AM
Mar-02-23 11:39AM
04:28AM
Mar-01-23 09:35AM
07:00AM
Feb-27-23 07:00AM
Feb-22-23 05:00PM
Feb-14-23 07:00AM
Feb-13-23 07:00AM
Feb-12-23 07:33AM
Feb-08-23 07:00AM
Feb-01-23 09:43AM
Jan-09-23 07:00AM
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SBLENDORIO GLENNDirectorMar 07 '24Option Exercise2.8015,00042,00083,596Mar 11 05:36 PM
RAAB MICHAELDirectorMar 05 '24Option Exercise2.8015,00042,00083,596Mar 06 05:22 PM
MCGLYNN MARGARET GDirectorMar 05 '24Option Exercise2.807,50021,00066,789Mar 06 05:21 PM
MCGLYNN MARGARET GDirectorMar 05 '24Sale13.407,500100,50059,289Mar 06 05:21 PM
MCGLYNN MARGARET GDirectorMar 04 '24Option Exercise2.807,50021,00066,789Mar 06 05:21 PM
MCGLYNN MARGARET GDirectorMar 04 '24Sale13.297,50099,67559,289Mar 06 05:21 PM
Campbell Bradley LPresident and CEOMar 01 '24Option Exercise10.5415,833166,904887,052Mar 05 05:14 PM
Crowley John FExecutive ChairmanMar 01 '24Sale13.3529,181389,543573,478Mar 05 05:14 PM
Campbell Bradley LPresident and CEOMar 01 '24Sale13.1415,833208,017871,219Mar 05 05:14 PM
Crowley John FExecutive ChairmanFeb 15 '24Sale13.8131,614436,551697,628Feb 20 05:23 PM
Clark David MichaelChief People OfficerFeb 15 '24Sale14.004,42761,978253,664Feb 20 05:20 PM
Campbell Bradley LPresident and CEOFeb 15 '24Sale14.004,16758,338871,219Feb 20 05:21 PM
Rosenberg EllenChief Legal OfficerFeb 07 '24Option Exercise5.1629,600152,736397,254Feb 08 04:40 PM
Rosenberg EllenChief Legal OfficerFeb 07 '24Sale13.0029,600384,818367,654Feb 08 04:40 PM
Rosenberg EllenChief Legal OfficerFeb 06 '24Option Exercise5.164002,064368,054Feb 08 04:40 PM
Rosenberg EllenChief Legal OfficerFeb 06 '24Sale13.004005,200367,654Feb 08 04:40 PM
Campbell Bradley LPresident and CEOFeb 01 '24Option Exercise10.5415,833166,904891,219Feb 05 07:22 PM
Crowley John FExecutive ChairmanFeb 01 '24Sale12.6231,614398,918750,838Feb 05 07:22 PM
Campbell Bradley LPresident and CEOFeb 01 '24Sale12.5615,833198,858875,386Feb 05 07:22 PM
Crowley John FExecutive ChairmanJan 22 '24Sale12.3655,327683,958782,452Jan 24 05:20 PM
Crowley John FExecutive ChairmanJan 16 '24Sale12.7831,614404,106837,779Jan 18 05:09 PM
Crowley John FExecutive ChairmanJan 10 '24Sale13.6531,614431,452869,393Jan 11 06:33 PM
Clark David MichaelChief People OfficerJan 09 '24Sale14.001,38419,376266,705Jan 09 06:08 PM
Prout SamanthaChief Accounting OfficerJan 09 '24Sale14.001,33718,71880,953Jan 09 06:07 PM
Prout SamanthaChief Accounting OfficerJan 08 '24Sale14.0030,767430,82782,290Jan 09 06:07 PM
Clark David MichaelChief People OfficerJan 08 '24Sale14.008,726122,164268,089Jan 09 06:08 PM
Campbell Bradley LPresident and CEOJan 02 '24Option Exercise10.5415,833166,904956,138Jan 04 06:35 PM
Rosenberg EllenChief Legal OfficerJan 02 '24Option Exercise5.1630,000154,800372,285Jan 04 06:24 PM
Rosenberg EllenChief Legal OfficerJan 02 '24Sale14.2130,000426,219342,285Jan 04 06:24 PM
Campbell Bradley LPresident and CEOJan 02 '24Sale14.2315,833225,380947,805Jan 04 06:35 PM
Castelli JeffChief Development OfficerDec 28 '23Sale14.5217,421252,902340,661Dec 29 05:18 PM
Rosenberg EllenChief Legal OfficerDec 27 '23Option Exercise5.165,00025,800347,285Dec 28 05:08 PM
Rosenberg EllenChief Legal OfficerDec 27 '23Sale14.075,00070,327342,285Dec 28 05:08 PM
Rosenberg EllenChief Legal OfficerDec 26 '23Option Exercise5.1630,000154,800372,285Dec 28 05:08 PM
Rosenberg EllenChief Legal OfficerDec 26 '23Sale14.0030,000420,084342,285Dec 28 05:08 PM
Prout SamanthaChief Accounting OfficerDec 26 '23Sale14.007,659107,228121,912Dec 28 05:09 PM
Castelli JeffChief Development OfficerDec 20 '23Sale13.101,65421,667358,082Dec 20 04:41 PM
Castelli JeffChief Development OfficerDec 19 '23Sale13.2517,500231,875359,736Dec 20 04:41 PM
Crowley John FExecutive ChairmanDec 15 '23Sale12.666,04376,516877,748Dec 19 05:55 PM
Campbell Bradley LPresident and CEODec 01 '23Option Exercise2.9411,70234,404803,863Dec 05 05:07 PM
Campbell Bradley LPresident and CEODec 01 '23Sale11.0811,702129,693792,161Dec 05 05:07 PM
Crowley John FExecutive ChairmanDec 01 '23Sale11.086,04366,956883,791Dec 05 05:03 PM
Crowley John FExecutive ChairmanNov 15 '23Sale10.846,04365,497889,834Nov 17 05:23 PM
Campbell Bradley LPresident and CEONov 01 '23Option Exercise2.9411,70034,398803,861Nov 03 07:38 PM
Campbell Bradley LPresident and CEONov 01 '23Sale10.9711,700128,391792,161Nov 03 07:38 PM
Crowley John FExecutive ChairmanNov 01 '23Sale10.976,04466,327895,877Nov 03 07:37 PM
Crowley John FExecutive ChairmanOct 16 '23Sale10.506,04463,449901,921Oct 18 07:57 PM
Campbell Bradley LPresident & CEOOct 02 '23Option Exercise2.9411,70034,398803,861Oct 04 06:57 PM
Campbell Bradley LPresident & CEOOct 02 '23Sale11.2411,700131,489792,161Oct 04 06:57 PM
Crowley John FExecutive ChairmanOct 02 '23Sale11.256,04467,967907,965Oct 04 06:58 PM
Crowley John FExecutive ChairmanSep 15 '23Sale13.066,04478,964914,009Sep 18 05:09 PM
Campbell Bradley LPresident & CEOSep 01 '23Option Exercise2.9411,70034,398810,254Sep 06 05:29 PM
Campbell Bradley LPresident & CEOSep 01 '23Sale12.9718,093234,648792,161Sep 06 05:29 PM
Crowley John FExecutive ChairmanSep 01 '23Sale12.986,04478,447920,053Sep 06 05:31 PM
Crowley John FExecutive ChairmanAug 15 '23Sale13.036,04478,734926,097Aug 16 05:33 PM
Prout SamanthaChief Accounting OfficerAug 09 '23Option Exercise11.0336,909407,116173,912Aug 11 05:28 PM
Prout SamanthaChief Accounting OfficerAug 09 '23Sale14.0136,909516,933137,003Aug 11 05:28 PM
Campbell Bradley LPresident & CEOAug 01 '23Option Exercise2.9411,70034,398818,554Aug 03 05:09 PM
Campbell Bradley LPresident & CEOAug 01 '23Sale13.3920,000267,874798,554Aug 03 05:09 PM
Crowley John FExecutive ChairmanAug 01 '23Sale13.356,04480,716932,141Aug 03 05:10 PM
Crowley John FExecutive ChairmanJul 17 '23Sale13.456,04481,263938,185Jul 19 05:45 PM
Campbell Bradley LPresident & CEOJul 13 '23Sale12.516,80085,091806,854Jul 14 05:06 PM
Campbell Bradley LPresident & CEOJul 12 '23Sale12.511,50018,759813,654Jul 14 05:06 PM
Campbell Bradley LPresident & CEOJul 03 '23Option Exercise2.9411,70034,398826,854Jul 06 06:25 PM
Campbell Bradley LPresident & CEOJul 03 '23Sale12.3111,700144,016815,154Jul 06 06:25 PM
Crowley John FExecutive ChairmanJul 03 '23Sale12.316,04474,406944,229Jul 06 06:26 PM
Crowley John FExecutive ChairmanJun 15 '23Sale13.046,04478,814950,273Jun 20 05:18 PM
Campbell Bradley LPresident & CEOJun 06 '23Sale12.508,300103,777815,154Jun 08 05:26 PM
Campbell Bradley LPresident & CEOJun 01 '23Option Exercise2.6411,70030,907835,154Jun 05 07:16 PM
Campbell Bradley LPresident & CEOJun 01 '23Sale11.3611,700132,942823,454Jun 05 07:16 PM
Crowley John FExecutive ChairmanJun 01 '23Sale11.366,04468,657956,317Jun 05 07:16 PM
SBLENDORIO GLENNDirectorMay 18 '23Option Exercise3.3215,00049,80086,719May 19 05:13 PM
Crowley John FExecutive ChairmanMay 15 '23Sale11.186,04467,577962,361May 17 06:20 PM
Campbell Bradley LPresident & CEOMay 01 '23Option Exercise2.4511,70028,665835,154May 03 04:31 PM
Campbell Bradley LPresident & CEOMay 01 '23Sale11.8011,700138,093823,454May 03 04:31 PM
Crowley John FExecutive ChairmanMay 01 '23Sale11.806,04471,335968,405May 03 04:35 PM
Crowley John FExecutive ChairmanApr 17 '23Sale11.666,04470,502974,449Apr 19 05:45 PM
Campbell Bradley LPresident & CEOApr 03 '23Option Exercise2.4511,70028,665835,154Apr 05 08:25 PM
Campbell Bradley LPresident & CEOApr 03 '23Sale11.2111,700131,207823,454Apr 05 08:25 PM
Crowley John FExecutive ChairmanApr 03 '23Sale11.226,04467,787980,493Apr 05 08:26 PM